Professor Bill Sessa, former Pfizer Chief Scientific Officer, takes the lead on Isomab's Scientific Advisory Board to advance its cardiovascular therapies.

Isomab Ltd has released a landmark study reassuring the safety of angiogenic therapies in treating coronary artery disease, targeting innovative treatments and paving the way for future discoveries.

First comprehensive systematic review provides insights into the long-term safety profile of angiogenic approaches in coronary artery disease Data shows no evidence of increased cancer or retinopathy, resolving long-standing safety questions that have limited progress across the field...

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

IsomAb has appointed Dr Philip Brainin as CEO and member of the Board of Directors.

IsomAb Ltd has appointed Dr. Philip Brainin as CEO, leading efforts to advance ISM-001, a groundbreaking treatment for chronic stable angina, into clinical development.

IsomAb Ltd announces the appointments of Dr. Shi Yin Foo as Non-Executive Director and Dr. Gary Burgess as Chief Medical Officer to propel its innovative drug development.

Advancing lead asset ISM-001 for Chronic Stable Angina into clinical development Strong preclinical data demonstrates ISM-001's novel disease-modifying mechanism to re-establish healthy angiogenesis Chronic Stable Angina is a major undertreated condition affecting 9 million US patients Dr....

Aim to accelerate progress of lead candidate ISM-001 for peripheral ischaemia to clinic NOTTINGHAM, England, Feb. 25, 2025 /PRNewswire/ -- IsomAb Ltd, a UK-based biotechnology company developing novel isoform-specific disease modifying antibody…